Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

Kimberly L. Katz; Katherine Rupley; Jacquelyn Sink; Adele Shuley; Alice B. Gottlieb

doi:10.1177/2475530318788943

Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

Kimberly L. Katz, Katherine Rupley, Jacquelyn Sink, Adele Shuley, Alice B. Gottlieb

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions. Observations: Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient’s vitiligo. Conclusion: While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo.

Original language	English
Pages (from-to)	126-130
Number of pages	5
Journal	Journal of Psoriasis and Psoriatic Arthritis
Volume	3
Issue number	4
DOIs	https://doi.org/10.1177/2475530318788943
State	Published - 1 Oct 2018
Externally published	Yes

Keywords

IL-17
Th17
biologic
interleukin 17
ixekizumab
psoriasis
vitiligo

Access to Document

10.1177/2475530318788943

Cite this

@article{2bd1cf6cc0594cce877e7c698c2ecaa6,

title = "Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo",

abstract = "Background: Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions. Observations: Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient{\textquoteright}s vitiligo. Conclusion: While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo.",

keywords = "IL-17, Th17, biologic, interleukin 17, ixekizumab, psoriasis, vitiligo",

author = "Katz, {Kimberly L.} and Katherine Rupley and Jacquelyn Sink and Adele Shuley and Gottlieb, {Alice B.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018.",

year = "2018",

month = oct,

day = "1",

doi = "10.1177/2475530318788943",

language = "English",

volume = "3",

pages = "126--130",

journal = "Journal of Psoriasis and Psoriatic Arthritis",

issn = "2475-5303",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

AU - Katz, Kimberly L.

AU - Rupley, Katherine

AU - Sink, Jacquelyn

AU - Shuley, Adele

AU - Gottlieb, Alice B.

N1 - Publisher Copyright: © The Author(s) 2018.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions. Observations: Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient’s vitiligo. Conclusion: While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo.

AB - Background: Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions. Observations: Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient’s vitiligo. Conclusion: While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo.

KW - IL-17

KW - Th17

KW - biologic

KW - interleukin 17

KW - ixekizumab

KW - psoriasis

KW - vitiligo

UR - http://www.scopus.com/inward/record.url?scp=85077777883&partnerID=8YFLogxK

U2 - 10.1177/2475530318788943

DO - 10.1177/2475530318788943

M3 - Article

AN - SCOPUS:85077777883

SN - 2475-5303

VL - 3

SP - 126

EP - 130

JO - Journal of Psoriasis and Psoriatic Arthritis

JF - Journal of Psoriasis and Psoriatic Arthritis

IS - 4

ER -

Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo

Abstract

Keywords

Access to Document

Fingerprint

Cite this